New therapeutic agents in the management of HIV: an overview of darunavir for clinicians.
This overview will provide the reader with summarised information about darunavir, a new protease inhibitor licensed for the treatment of drug resistant HIV-infection. Darunavir is a promising new drug with good clinical efficacy data and safety profile. In this overview clinicians will be updated on clinical efficacy data, side-effects, resistance profile and drug interactions. The overview should give clinicians a sound understanding of when and how to use this new protease inhibitor in the treatment of HIV-infection.
Rotty
Jessica
J
Infectious Diseases Unit, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia. j.rotty@alfred.org.au
Hoy
Jennifer
J
D000818:Animals; D002983:Clinical Competence; D002986:Clinical Trials as Topic; D000069454:Darunavir; D004334:Drug Administration Schedule; D004347:Drug Interactions; D024882:Drug Resistance, Viral / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D010818:Practice Patterns, Physicians'; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D019562:Viral Load
D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir